Is Shuttle Pharmaceuticals Stock a Good Investment?
Shuttle Pharmaceuticals Investment Advice | SHPH |
- Examine Shuttle Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Shuttle Pharmaceuticals' leadership team and their track record. Good management can help Shuttle Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Shuttle Pharmaceuticals' business and its evolving consumer preferences.
- Compare Shuttle Pharmaceuticals' performance and market position to its competitors. Analyze how Shuttle Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Shuttle Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Shuttle Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Shuttle Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Shuttle Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Shuttle Pharmaceuticals Stock
Researching Shuttle Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.25. Shuttle Pharmaceuticals had not issued any dividends in recent years. The entity had 1:8 split on the 13th of August 2024.
To determine if Shuttle Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Shuttle Pharmaceuticals' research are outlined below:
| Shuttle Pharmaceuticals generated a negative expected return over the last 90 days | |
| Shuttle Pharmaceuticals has high historical volatility and very poor performance | |
| Shuttle Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Shuttle Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Shuttle Pharmaceuticals currently holds 1.09 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Shuttle Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Shuttle Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Shuttle Pharmaceuticals currently holds about 50.44 K in cash with (5.58 M) of positive cash flow from operations. | |
| Shuttle Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 19.0% of Shuttle Pharmaceuticals outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Why Five9 Shares Are Trading Higher By Around 13 Here Are 20 Stocks Moving Premarket - Benzinga India |
Shuttle Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Shuttle Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Shuttle Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Shuttle Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Shuttle Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Shuttle Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Shuttle Pharmaceuticals backward and forwards among themselves. Shuttle Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Shuttle Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 306.1 K | Ubs Group Ag | 2024-12-31 | 32.8 K | Geode Capital Management, Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 6.9 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-12-31 | 23.0 | Hrt Financial Llc | 2024-12-31 | 0.0 |
Shuttle Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.46 M.Market Cap |
|
Shuttle Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.00) | (1.05) | |
| Return On Capital Employed | (1.08) | (1.13) | |
| Return On Assets | (1.00) | (1.05) | |
| Return On Equity | (1.46) | (1.54) |
Determining Shuttle Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Shuttle Pharmaceuticals is a good buy. For example, gross profit margin measures Shuttle Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Shuttle Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Shuttle Pharmaceuticals' management efficiency
Shuttle Pharmaceuticals has return on total asset (ROA) of (1.1184) % which means that it has lost $1.1184 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2785) %, meaning that it created substantial loss on money invested by shareholders. Shuttle Pharmaceuticals' management efficiency ratios could be used to measure how well Shuttle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.05. The current Return On Capital Employed is estimated to decrease to -1.13. As of now, Shuttle Pharmaceuticals' Net Tangible Assets are increasing as compared to previous years. The Shuttle Pharmaceuticals' current Total Current Assets is estimated to increase to about 6.8 M, while Other Assets are projected to decrease to 5,184.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.23 | 0.24 | |
| Tangible Book Value Per Share | 0.23 | 0.24 | |
| Enterprise Value Over EBITDA | (12.72) | (13.36) | |
| Price Book Value Ratio | 16.42 | 15.60 | |
| Enterprise Value Multiple | (12.72) | (13.36) | |
| Price Fair Value | 16.42 | 15.60 | |
| Enterprise Value | 64.9 M | 61.6 M |
Effective leadership at Shuttle Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.255 |
Basic technical analysis of Shuttle Stock
As of the 26th of February, Shuttle Pharmaceuticals has the Variance of 25.59, coefficient of variation of (939.85), and Risk Adjusted Performance of (0.07). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Shuttle Pharmaceuticals, as well as the relationship between them.Shuttle Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Shuttle Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Shuttle Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Shuttle Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dritschilo Anatoly over three months ago Disposition of 8372 shares by Dritschilo Anatoly of Shuttle Pharmaceuticals at 1.605 subject to Rule 16b-3 | ||
Lorber Timothy J. over six months ago Disposition of tradable shares by Lorber Timothy J. of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Schafer Joshua over six months ago Disposition of tradable shares by Schafer Joshua of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Vander Hoek Michael over six months ago Acquisition by Vander Hoek Michael of 100000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Jacobs Bette over a year ago Sale by Jacobs Bette of 4157 shares of Shuttle Pharmaceuticals | ||
Dritschilo Anatoly over a year ago Bona fide gift to Dritschilo Anatoly of 2100000 shares of Shuttle Pharmaceuticals subject to Section 16 | ||
Brown Milton over a year ago Acquisition by Brown Milton of 25000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 |
Understand Shuttle Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Shuttle Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 4.02 | |||
| Coefficient Of Variation | (939.85) | |||
| Standard Deviation | 5.06 | |||
| Variance | 25.59 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 20.74 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 11.36 | |||
| Skewness | 0.8586 | |||
| Kurtosis | 0.2644 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 4.02 | |||
| Coefficient Of Variation | (939.85) | |||
| Standard Deviation | 5.06 | |||
| Variance | 25.59 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 20.74 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 11.36 | |||
| Skewness | 0.8586 | |||
| Kurtosis | 0.2644 |
Consider Shuttle Pharmaceuticals' intraday indicators
Shuttle Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Shuttle Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 11757.7 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.61 | |||
| Day Typical Price | 0.6 | |||
| Price Action Indicator | (0.01) | |||
| Relative Strength Index | 36.57 |
Shuttle Stock media impact
Far too much social signal, news, headlines, and media speculation about Shuttle Pharmaceuticals that are available to investors today. That information is available publicly through Shuttle media outlets and privately through word of mouth or via Shuttle internal channels. However, regardless of the origin, that massive amount of Shuttle data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Shuttle Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Shuttle Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Shuttle Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Shuttle Pharmaceuticals alpha.
Shuttle Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Shuttle Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Shuttle Pharmaceuticals Corporate Management
| Michael Starkweather | VP Devel | Profile | |
| CSC MD | Chief CoFounder | Profile | |
| Timothy CPA | Chief Officer | Profile | |
| Gene Esq | General Counsel | Profile | |
| Mira Jung | CoFounder Biology | Profile | |
| Tyvin MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Shuttle Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.